Recursion Pharmaceuticals
RXRX
RXRX
247 hedge funds and large institutions have $2.12B invested in Recursion Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 88 increasing their positions, 53 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
3% more capital invested
Capital invested by funds: $2.06B → $2.12B (+$60M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
27% less call options, than puts
Call options by funds: $15.6M | Put options by funds: $21.4M
Holders
247
Holding in Top 10
6
Calls
$15.6M
Puts
$21.4M
Top Buyers
| 1 | +$39.2M | |
| 2 | +$11.6M | |
| 3 | +$11.5M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.15M |
| 5 |
JP Morgan Chase
New York
|
+$6.99M |
Top Sellers
| 1 | -$31.8M | |
| 2 | -$17.9M | |
| 3 | -$16.3M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.7M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$8.94M |